multiple immunotherapeutic options: clinical decision ......peter h. o’donnell 20 minutes case...
TRANSCRIPT
-
Copyright © 2020 Merck Sharp & Dohme Corp., a subsidiary of Merck & Co., Inc., Kenilworth, NJ, USA. All rights reserved. 209786-2
Chair: Brian Rini
AGENDA5 minutes Introduction and Objectives
Brian Rini
20 minutes Overview of Checkpoint Inhibitors in Advanced RCCThomas Powles
20 minutes Case Study Patient With aRCC Suited for Potentially Either IO/IO or IO/TKI OptionBrian Rini
20 minutes Checkpoint Inhibitor Monotherapy in Metastatic UCPeter H. O’Donnell
20 minutes Case Study Patient With mUC Facing Treatment Decisions(1L, cis-eligible, progresses to platinum-refractory)Ajjai Alva
5 minutes Closing RemarksBrian Rini
CHAIR Brian RiniVanderbilt-Ingram Cancer Center Nashville, Tennessee, USA
FACULTYAjjai AlvaUniversity of Michigan Health Center Ann Arbor, Michigan, USA
Peter H. O’Donnell University of Chicago Chicago, Illinois, USA
Thomas Powles Barts Cancer Institute London, United Kingdom
ESMO Virtual Congress 2020 Industry Satellite Symposium
Multiple Immunotherapeutic Options: Clinical Decision Making in Advanced Renal Cell Carcinoma and Urothelial Carcinoma
Satellite Symposium Sponsored by MSD
This symposium is fully funded and organised by MSD and MSD product will be mentioned. Refer to your local Prescribing Information before prescribing, as it may differ between countries. Adverse events should be reported as per your local guidance.
Virtual Symposium Available on Demand 14 – 29 September 2020Live Q&A on Saturday, 26 September (16:45 – 17:15 CET)